Multicenter phase II study of weekly oral vinorelbine for stage IV non-small-cell lung cancer

Everett E. Vokes, Richard K. Rosenberg, Mohammed Jahanzeb, Johnny B. Craig, Richard J. Gralla, Chandra P. Belani, Stephen E. Jones, Joseph W. Bigley, John A. Hohneker

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Purpose: We initiated a large multicenter phase II trial in stage IV non-small-cell lung cancer (NSCLC) to evaluate the activity and safety of an oral gelatin-based formation of vinorelbine. Patients and Methods: Twenty-three centers participated in this uncontrolled phase II study, which accrued patients between August 1991 and March 1992. Eligible patients had previously untreated measurable or assessable stage IV NSCLC, age more than 18 years, and Karnofsky performance status ≥ 70%. The treatment plan initially was to administer 100 mg/m2/wk of oral vinorelbine or 80 mg/m2/wk for patients who had received prior radiation therapy. After the observation of grade IV granulocytopenia in six of the first 25 patients, subsequent doses were reduced by 40 mg (one capsule) in all patients. Results: One hundred sixty-two patients were treated: 138 with measurable and 24 with assessable disease. One hundred two patients were men and 60 women. The mean age was 62 years (range, 36 to 83). The overall response rate was 14.5% for patients with measurable disease (95% confidence interval, 9.3% to 21.7%). The median time to treatment failure (TTF) for all patients was 9 weeks. The median survival time was 29 weeks; the 1-year survival rate was 22%. Toxicities included grade 3 or 4 neutropenia in 40%, which was dependent on the vinorelbine dose. Other toxicities included mild to moderate nausea/vomiting, diarrhea, and stomatitis. The mean dose intensity of vinorelbine was 53 mg/m2. Conclusion: Oral vinorelbine administered once weekly is an active agent in stage IV NSCLC. The median survival time of 29 weeks is similar to that achieved with single-agent intravenous vinorelbine and more aggressive cisplatin-based combinations. Further studies of this compound in the palliative-intent care setting appear to be indicated.

Original languageEnglish (US)
Pages (from-to)637-644
Number of pages8
JournalJournal of Clinical Oncology
Volume13
Issue number3
StatePublished - Mar 1995
Externally publishedYes

Fingerprint

Oral Stage
Non-Small Cell Lung Carcinoma
vinorelbine
Karnofsky Performance Status
Stomatitis
Agranulocytosis
Survival
Gelatin
Neutropenia
Treatment Failure
Palliative Care
Nausea
Cisplatin
Capsules
Vomiting
Diarrhea
Radiotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Vokes, E. E., Rosenberg, R. K., Jahanzeb, M., Craig, J. B., Gralla, R. J., Belani, C. P., ... Hohneker, J. A. (1995). Multicenter phase II study of weekly oral vinorelbine for stage IV non-small-cell lung cancer. Journal of Clinical Oncology, 13(3), 637-644.

Multicenter phase II study of weekly oral vinorelbine for stage IV non-small-cell lung cancer. / Vokes, Everett E.; Rosenberg, Richard K.; Jahanzeb, Mohammed; Craig, Johnny B.; Gralla, Richard J.; Belani, Chandra P.; Jones, Stephen E.; Bigley, Joseph W.; Hohneker, John A.

In: Journal of Clinical Oncology, Vol. 13, No. 3, 03.1995, p. 637-644.

Research output: Contribution to journalArticle

Vokes, EE, Rosenberg, RK, Jahanzeb, M, Craig, JB, Gralla, RJ, Belani, CP, Jones, SE, Bigley, JW & Hohneker, JA 1995, 'Multicenter phase II study of weekly oral vinorelbine for stage IV non-small-cell lung cancer', Journal of Clinical Oncology, vol. 13, no. 3, pp. 637-644.
Vokes EE, Rosenberg RK, Jahanzeb M, Craig JB, Gralla RJ, Belani CP et al. Multicenter phase II study of weekly oral vinorelbine for stage IV non-small-cell lung cancer. Journal of Clinical Oncology. 1995 Mar;13(3):637-644.
Vokes, Everett E. ; Rosenberg, Richard K. ; Jahanzeb, Mohammed ; Craig, Johnny B. ; Gralla, Richard J. ; Belani, Chandra P. ; Jones, Stephen E. ; Bigley, Joseph W. ; Hohneker, John A. / Multicenter phase II study of weekly oral vinorelbine for stage IV non-small-cell lung cancer. In: Journal of Clinical Oncology. 1995 ; Vol. 13, No. 3. pp. 637-644.
@article{e2d8aced4f2347b093bfaac98c398f10,
title = "Multicenter phase II study of weekly oral vinorelbine for stage IV non-small-cell lung cancer",
abstract = "Purpose: We initiated a large multicenter phase II trial in stage IV non-small-cell lung cancer (NSCLC) to evaluate the activity and safety of an oral gelatin-based formation of vinorelbine. Patients and Methods: Twenty-three centers participated in this uncontrolled phase II study, which accrued patients between August 1991 and March 1992. Eligible patients had previously untreated measurable or assessable stage IV NSCLC, age more than 18 years, and Karnofsky performance status ≥ 70{\%}. The treatment plan initially was to administer 100 mg/m2/wk of oral vinorelbine or 80 mg/m2/wk for patients who had received prior radiation therapy. After the observation of grade IV granulocytopenia in six of the first 25 patients, subsequent doses were reduced by 40 mg (one capsule) in all patients. Results: One hundred sixty-two patients were treated: 138 with measurable and 24 with assessable disease. One hundred two patients were men and 60 women. The mean age was 62 years (range, 36 to 83). The overall response rate was 14.5{\%} for patients with measurable disease (95{\%} confidence interval, 9.3{\%} to 21.7{\%}). The median time to treatment failure (TTF) for all patients was 9 weeks. The median survival time was 29 weeks; the 1-year survival rate was 22{\%}. Toxicities included grade 3 or 4 neutropenia in 40{\%}, which was dependent on the vinorelbine dose. Other toxicities included mild to moderate nausea/vomiting, diarrhea, and stomatitis. The mean dose intensity of vinorelbine was 53 mg/m2. Conclusion: Oral vinorelbine administered once weekly is an active agent in stage IV NSCLC. The median survival time of 29 weeks is similar to that achieved with single-agent intravenous vinorelbine and more aggressive cisplatin-based combinations. Further studies of this compound in the palliative-intent care setting appear to be indicated.",
author = "Vokes, {Everett E.} and Rosenberg, {Richard K.} and Mohammed Jahanzeb and Craig, {Johnny B.} and Gralla, {Richard J.} and Belani, {Chandra P.} and Jones, {Stephen E.} and Bigley, {Joseph W.} and Hohneker, {John A.}",
year = "1995",
month = "3",
language = "English (US)",
volume = "13",
pages = "637--644",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "3",

}

TY - JOUR

T1 - Multicenter phase II study of weekly oral vinorelbine for stage IV non-small-cell lung cancer

AU - Vokes, Everett E.

AU - Rosenberg, Richard K.

AU - Jahanzeb, Mohammed

AU - Craig, Johnny B.

AU - Gralla, Richard J.

AU - Belani, Chandra P.

AU - Jones, Stephen E.

AU - Bigley, Joseph W.

AU - Hohneker, John A.

PY - 1995/3

Y1 - 1995/3

N2 - Purpose: We initiated a large multicenter phase II trial in stage IV non-small-cell lung cancer (NSCLC) to evaluate the activity and safety of an oral gelatin-based formation of vinorelbine. Patients and Methods: Twenty-three centers participated in this uncontrolled phase II study, which accrued patients between August 1991 and March 1992. Eligible patients had previously untreated measurable or assessable stage IV NSCLC, age more than 18 years, and Karnofsky performance status ≥ 70%. The treatment plan initially was to administer 100 mg/m2/wk of oral vinorelbine or 80 mg/m2/wk for patients who had received prior radiation therapy. After the observation of grade IV granulocytopenia in six of the first 25 patients, subsequent doses were reduced by 40 mg (one capsule) in all patients. Results: One hundred sixty-two patients were treated: 138 with measurable and 24 with assessable disease. One hundred two patients were men and 60 women. The mean age was 62 years (range, 36 to 83). The overall response rate was 14.5% for patients with measurable disease (95% confidence interval, 9.3% to 21.7%). The median time to treatment failure (TTF) for all patients was 9 weeks. The median survival time was 29 weeks; the 1-year survival rate was 22%. Toxicities included grade 3 or 4 neutropenia in 40%, which was dependent on the vinorelbine dose. Other toxicities included mild to moderate nausea/vomiting, diarrhea, and stomatitis. The mean dose intensity of vinorelbine was 53 mg/m2. Conclusion: Oral vinorelbine administered once weekly is an active agent in stage IV NSCLC. The median survival time of 29 weeks is similar to that achieved with single-agent intravenous vinorelbine and more aggressive cisplatin-based combinations. Further studies of this compound in the palliative-intent care setting appear to be indicated.

AB - Purpose: We initiated a large multicenter phase II trial in stage IV non-small-cell lung cancer (NSCLC) to evaluate the activity and safety of an oral gelatin-based formation of vinorelbine. Patients and Methods: Twenty-three centers participated in this uncontrolled phase II study, which accrued patients between August 1991 and March 1992. Eligible patients had previously untreated measurable or assessable stage IV NSCLC, age more than 18 years, and Karnofsky performance status ≥ 70%. The treatment plan initially was to administer 100 mg/m2/wk of oral vinorelbine or 80 mg/m2/wk for patients who had received prior radiation therapy. After the observation of grade IV granulocytopenia in six of the first 25 patients, subsequent doses were reduced by 40 mg (one capsule) in all patients. Results: One hundred sixty-two patients were treated: 138 with measurable and 24 with assessable disease. One hundred two patients were men and 60 women. The mean age was 62 years (range, 36 to 83). The overall response rate was 14.5% for patients with measurable disease (95% confidence interval, 9.3% to 21.7%). The median time to treatment failure (TTF) for all patients was 9 weeks. The median survival time was 29 weeks; the 1-year survival rate was 22%. Toxicities included grade 3 or 4 neutropenia in 40%, which was dependent on the vinorelbine dose. Other toxicities included mild to moderate nausea/vomiting, diarrhea, and stomatitis. The mean dose intensity of vinorelbine was 53 mg/m2. Conclusion: Oral vinorelbine administered once weekly is an active agent in stage IV NSCLC. The median survival time of 29 weeks is similar to that achieved with single-agent intravenous vinorelbine and more aggressive cisplatin-based combinations. Further studies of this compound in the palliative-intent care setting appear to be indicated.

UR - http://www.scopus.com/inward/record.url?scp=0028931164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028931164&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 637

EP - 644

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 3

ER -